Chrysos (C79) investor relations material

Executive summary

• Achieved record FY26 revenue and EBITDA at the upper end of guidance, driven by strong global adoption and high utilisation of PhotonAssay technology, with record sample volumes processed.

• Expanded contracted fleet to 87 units, with 46 deployed at year-end and six more being installed; 24 new lease agreements signed in FY26 and four post-period.

• Strengthened operating platform and balance sheet, supporting next-stage growth and a manufacturing cadence of 18 units per year.

• Sample volumes reached a record 11.3 million for the year, up 67% year-over-year.

Financial highlights

• Revenue increased 33% year-over-year to $88.1m (AUD 88.1 million); EBITDA rose 68% to $27.2m, with margin expanding from 24% to 31%.

• Net profit of $1.8m delivered; operating cash flow up 103% to $17.9m.

• Gross profit up 32% to $66.8m, with gross margins sustained at 70%-80%.

• MMAP revenue $62.5m (+12%), AAC revenue $25.5m (+153%), now 29% of revenue.

• International revenue accounted for 56% of group total, validating global rollout.

Outlook and guidance

• FY27 revenue guidance: $108m–$118m; EBITDA guidance: $35m–$42m, both at constant currency.

• Plan to double deployed units over three years, supported by strong contracted pipeline and manufacturing capacity.

• Focus on disciplined cost management and maintaining manufacturing cadence.

• Revenue increasingly linked to production volumes, supporting lower earnings volatility.

• Expansion into non-gold commodities planned to broaden addressable market.